Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 4143, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
CFH P08603 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CFD K7ERG9 Bereman et al. 2018 ALS Control CSF Up 33 ALS, 30 control N/A N/A N/A
CFD P00746 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CFD P00746 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CFD P00746 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CFD P00746 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CFB P00751 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CFB P00751 Hayashi et al. 2020 ALS Control CSF exosome-enriched fractions Down 3 ALS, 3 control N/A 74.3 N/A
CFB P00751 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
CFAP20 Q9Y6A4 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CFAI P05156 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
CEP295 Q9C0D2 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CEP170 Q5SW79 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CEP164 Q9UPV0 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CEP135 Q66GS9 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CENPF P49454 Oh et al. 2023 ALS Control CSF Up 20 ALS, 20 control N/A 59 N/A
CEND1 Q8N111 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CEMIP Q8WUJ3 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CEMIP Q8WUJ3 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CEMIP Q8WUJ3 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CELF2 O95319 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CECR1 Q9NZK5 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CECR1 Q9NZK5 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CECR1 Q9NZK5 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CDV3 Q9UKY7 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CDK5 Q00535 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
CDK5 Q00535 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CDK18 Q07002 Umoh et al. 2018 ALS Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
CDH5 P33151 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CDH5 P33151 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CDH5 P33151 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CDH20 Q9HBT6 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CDH20 Q9HBT6 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CDH2 P19022 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CDH2 P19022 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CDH19 Q9H159 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CDH13 P55290 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CDH1 P12830 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CDH1 P12830 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CDH1 P12830 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CDH1 P12830 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CDCA2 Q69YH5 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CDC42 P60953 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CDC42 P60953 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CDC42 P60953 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CDC37L1 Q7L3B6 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CD99L2 Q8TCZ2 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD93 Q9NPY3 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD9 P21926 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD81 E9PJK1 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CD7 J3QLM0 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CD5L O43866 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CD5L O43866 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD5L O43866 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CD5L O43866 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CD5L O43866 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CD48 P09326 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CD48 P09326 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CD44 P16070 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CD44 P16070 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD44 P16070 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CD44 P16070 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CD44 H0YD13 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CD3E E9PSH8 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CD300A Q9UGN4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD300A Q9UGN4 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
CD22 P20273 Berrone et al. 2023 sALS Control Plasma Up 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CD163 Q86VB7 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CD163 Q86VB7 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CD163 Q86VB7 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CD163 Q86VB7 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD163 Q86VB7 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CD14 P08571 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CD14 P08571 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CD14 P08571 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD14 P08571 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CD109 Q6YHK3 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CD109 Q6YHK3 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CD109 Q6YHK3 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CD109 Q6YHK3 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CCT6A P40227 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CCT5 B7ZAR1 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CCT2 P78371 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CCSMST1 Q4G0I0 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CCS J3KNF4 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CCL25 O15444 Berrone et al. 2023 fALS Control Plasma Down 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CCL18 P55774 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CCL17 Q92583 Berrone et al. 2023 ALS Control Plasma Up 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CCL17 Q92583 Berrone et al. 2023 sALS Control Plasma Up 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CCL14 Q16627 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CCL14 Q16627 Oeckl et al. 2020 gALS Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CCL14 Q16627 Oeckl et al. 2020 sALS Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74) N/A
CCL14 Q16627 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CCK P06307 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CCK P06307 Oeckl et al. 2020 gALS Control CSF Down 14 gALS, 16 control 54 (52-69) 62 (53-75) N/A
CCDC88C Q9P219 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CCDC19 Q9UL16 Hayashi et al. 2020 ALS Control CSF exosome-enriched fractions Down 3 ALS, 3 control N/A 74.3 N/A
CCDC180 Q9P1Z9 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CCDC18 Q5T9S5 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CCDC154 A6NI56 Zhou et al. 2023 BO-ALS SO-ALS CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A